gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

Tumor specific MUC1 glycosylation correlates with improved post-surgical survival of non-small cell lung cancer patients with lymphatic or distant metastasis

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Rainer Wiewrodt - III. Med. Klinik, Universitätsklinikum, Mainz
  • Andreas Kuemmel - III. Med. Klinik, Universitätsklinikum, Mainz
  • Kristjan Single - III. Med. Klinik, Universitätsklinikum, Mainz
  • Fernando Bittinger - Pathologie, Universitätsklinikum, Mainz
  • Andreas Faldum - Medizinische Statistik, IMBEI, Universität Mainz
  • Martin Sebastian - III. Med. Klinik, Universitätsklinikum, Mainz
  • Christian Taube - III. Med. Klinik, Universitätsklinikum, Mainz
  • Steffen Goletz - Glycotope GmbH, Berlin
  • Roland Buhl - III. Med. Klinik, Universitätsklinikum, Mainz

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO156

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk266.shtml

Published: March 20, 2006

© 2006 Wiewrodt et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

MUC1 (CD227)is expressed on glandular epithelia and on epithelial tumors. Tumor MUC1 differs from normal MUC1 by modified glycan side chains. The clinical relevance of aberrant glycosylation in lung cancer is not well known. Therefore, survival following surgical resection of lung cancer was correlated with MUC1 expression on paraffin embedded material using a novel, tumor specific monoclonal MUC1 antibody (derivate from clone A76-A/C7) designed for immunotherapy. Antigen binding of A76-A/C7 has a very high glycosylation dependency as described in the current literature. Surgical samples from 103 NSCLC patients (71,8% male; mean age 63±10 yr.) with lung cancer of all stages (stage I 55%; stage II 25%; stage III 15%; stage IV 5%) were evaluated according to Remmele’s Immunoreactive Score (IRS). An IRS value of > 3 was considered as positive. Although A76-A/C7/MUC1 positive staining did not show an influence on patients’ survival (p>0,1), subgroup analysis of patients with an advanced tumor disease.